Datapoint: FDA Approves Sun Pharma’s JAK Inhibitor
The FDA last week approved Sun Pharma’s oral JAK inhibitor Leqselvi (deuruxolitinib) for the treatment of severe alopecia areata in adult patients, becoming the third JAK therapy in the rapidly growing space. Eli Lilly’s Olumiant (baricitinib) in 2022 became the first systemic therapy available to treat alopecia areata. The JAK inhibitor currently holds covered or better status for 70% of all insured lives under the pharmacy benefit, though utilization management (UM) restrictions are required for most patients. It was followed in 2023 by Pfizer’s JAK inhibitor Litfulo (ritlecitinib), which holds 64% covered or better status, also largely with UM applied.
SOURCE: MMIT Analytics, as of 7/29/24